BioMedican Pitches Cannabinoid Biosynthesis Investing; Cultivated Market Sprouts More Deals
Executive Summary
BioMedican needs support until it can begin generating revenues and conduct an IPO. Businesses already marketing cannabinoid supplements receive more funding, or in some cases are acquired, as well as expand distribution.